TY - JOUR T1 - STIMULATE-ICP-CAREINEQUAL - Defining usual care and examining inequalities in Long Covid support: protocol for a mixed-methods study (part of STIMULATE-ICP: Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) JF - medRxiv DO - 10.1101/2022.05.06.22274658 SP - 2022.05.06.22274658 AU - Mel Ramasawmy AU - Yi Mu AU - Donna Clutterbuck AU - Marija Pantelic AU - Gregory Y. H. Lip AU - Christina van der Feltz-Cornelis AU - Dan Wootton AU - Nefyn H Williams AU - Hugh Montgomery AU - Rita Mallinson Cookson AU - Emily Attree AU - Mark Gabbay AU - Melissa Heightman AU - Nisreen A Alwan AU - Amitava Banerjee AU - Paula Lorgelly AU - the STIMULATE-ICP consortium Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/07/2022.05.06.22274658.abstract N2 - Introduction Individuals with Long Covid represent a new and growing patient population. In England, fewer than 90 Long Covid clinics deliver assessment and treatment informed by NICE guidelines. However, a paucity of clinical trials or longitudinal cohort studies means that the epidemiology, clinical trajectory, healthcare utilisation and effectiveness of current Long Covid care are poorly documented, and that neither evidence-based treatments nor rehabilitation strategies exist. In addition, and in part due to pre-pandemic health inequalities, access to referral and care varies, and patient experience of the Long Covid care pathways can be poor.In a mixed methods study, we therefore aim to: (1) describe the usual healthcare, outcomes and resource utilisation of individuals with Long Covid; (2) assess the extent of inequalities in access to Long Covid care, and specifically to understand Long Covid patients’ experiences of stigma and discrimination.Methods and analysis A mixed methods study will address our aims. Qualitative data collection from patients and health professionals will be achieved through surveys, interviews and focus group discussions, to understand their experience and document the function of clinics. A patient cohort study will provide an understanding of outcomes and costs of care. Accessible data will be further analysed to understand the nature of Long Covid, and the care received.Ethics and dissemination Ethical approval was obtained from South Central - Berkshire Research Ethics Committee (reference 303958). The dissemination plan will be decided by the patient and public involvement and engagement (PPIE) group members and study Co-Is, but will target 1) policy makers, and those responsible for commissioning and delivering Long Covid services, 2) patients and the public, and 3) academics.Competing Interest StatementHM has advised Axcella Health Inc on trial design in Long Covid; has consulted for AstraZeneca on monoclonal antibody use in acute covid prevention and treatment; and Millfield Medical in the development of a new CPAP machine. CvdF-C has no competing interests to declare. GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. No fees are received personally.Funding StatementThis work was supported by NIHR grant number [NIHR COV-LT2-0043] (https://www.arc-nt.nihr.ac.uk/research/projects/stimulate-icp-improving-diagnosis-treatment-and-care-of-long-covid/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the NHS South Central - Berkshire Research Ethics Committee (reference 303958).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a protocol paper; no data are available from this work at present. ER -